nach oben

Erschienen in:

01.04.2014 | Original Article

Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?

verfasst von: Anna-Regina Scheffer, Stefan Holdenrieder, Glen Kristiansen, Alexander von Ruecker, Stefan C. Müller, Jörg Ellinger

Erschienen in: World Journal of Urology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recent studies indicate that circulating microRNAs in serum/plasma are a novel class of non-invasive biomarkers with diagnostic and prognostic information. So far, circulating microRNAs have not been analyzed in patients with bladder cancer.

Methods

We collected serum from patients with non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC) and non-malignant urological disease. Total RNA was isolated from 400 μl of serum using the mirVana PARIS Kit; the artificial cel-miR-39 was spiked-in prior to RNA isolation to control different RNA isolation efficiencies. Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort (NMIBC, n = 11, MIBC, n = 10; controls, n = 10). The most promising serum microRNAs were tested in a validation cohort (NMIBC, n = 65, MIBC, n = 61; controls, n = 105).

Results

The RNA recovery was similar in patients with NMIBC, MIBC and control subjects. The analysis of serum microRNA levels in the marker identification cohort indicated that serum miR-141 and miR-639 levels were increased in bladder cancer patients compared to CTRL. The analysis of these miR-141 and miR-639 in the validation cohort demonstrated that microRNA levels were similar in bladder cancer patients and control subjects. Furthermore, microRNA levels were not correlated with clinicopathological parameters (pT-stage, metastasis, grading).

Conclusions

The analysis of serum miR-141 and miR-639 levels does not seem to be helpful in the diagnosis or prognosis of BCA.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724–733PubMedCrossRef

Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087–2092PubMedCrossRef

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675PubMedCrossRef

Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5:e13735PubMedCentralPubMedCrossRef

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y et al (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721–1726PubMedCrossRef

Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J (2011) Circulating microRNAs (miRNA) in serum of patients With prostate cancer. Urology 77:1265PubMedCrossRef

Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F et al (2011) MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787PubMedCentralPubMedCrossRef

Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392PubMedCrossRef

10.

Baffa R, Fassan M, Volinia S, O’Hara B, Liu CG, Palazzo JP et al (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219:214–221PubMedCrossRef

11.

Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481PubMedCentralPubMedCrossRef

12.

Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L et al (2011) MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 6:e18286PubMedCentralPubMedCrossRef

13.

Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H et al (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124:2236–2242PubMedCrossRef

14.

Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860PubMedCrossRef

15.

Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S et al (2010) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28:39–48PubMedCrossRef

16.

Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K et al (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125:345–352PubMedCrossRef

17.

Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, et al (2010) Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 11(1513–7368 (Print)):905–911

18.

Wang G, Zhang H, He H, Tong W, Wang B, Liao G et al (2010) Up-regulation of microRNA in bladder tumor tissue is not common. Int Urol Nephrol 42:95–102PubMedCrossRef

19.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518PubMedCentralPubMedCrossRef

20.

Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616PubMedCrossRef

21.

Gonzales JC, Fink LM, Goodman OB, Symanowski JT, Vogelzang NJ, Ward DC (2011) Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9:39–45PubMedCrossRef

22.

Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M et al (2011) Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6:e17745PubMedCentralPubMedCrossRef

23.

Liu X-G, Zhu W-Y, Huang Y–Y, Ma L-N, Zhou S-Q, Wang Y-K et al (2012) High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 29:618–626PubMedCrossRef

24.

Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y et al (2012) MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 55:2365–2372CrossRef

25.

Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 56:270–276PubMedCrossRef

26.

Wang G, Chan ES-Y, Kwan BC-H, Li PK-T, Yip SK-H, Szeto C–C et al (2012) Expression of microRNAs in the Urine of Patients With Bladder Cancer. Clin Genitourin Cancer 10:106–113PubMedCrossRef

27.

Sanders I, Holdenrieder S, Walgenbach-Brünagel G, von Rücker A, Kristiansen G, Müller SC, et al Evaluation of reference genes for the analysis fo serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (in press) (doi: 10.1111/j.1442-2042.2012.03082.x)

Titel: Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?
verfasst von: Anna-Regina Scheffer
Stefan Holdenrieder
Glen Kristiansen
Alexander von Ruecker
Stefan C. Müller
Jörg Ellinger
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 2/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-012-1010-2

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?